News NetraMark Holdings Inc. Canadian Securities Exchange

Stocks

AIAI

CA64119M1059

Software

End-of-day quote Canadian Securities Exchange 2026-02-20			5-day change	1st Jan Change
1.070 ^CAD	-.--%		-3.77%	-7.27%

Sep. 10	NetraMark Holdings Inc Publishes Peer-Reviewed Study Demonstrating NetraAI Uncovers Clinical Trial Signals Missed By Conventional AI And Foundation Models	CI
Sep. 01	Netramark Holdings Inc. Announces Appointment of Keith M. Fournier to Board of Directors	CI

All News

Mentions Relevance

Sep. 10	NetraMark Holdings Inc Publishes Peer-Reviewed Study Demonstrating NetraAI Uncovers Clinical Trial Signals Missed By Conventional AI And Foundation Models	CI
Sep. 10	Peer-Reviewed Study Published in MDPI’s AI Journal Shows NetraAI Uncovers Clinical Trial Signals Missed by Conventional AI and Foundation Models	AQ
Sep. 08	NetraMark Appoints Former Global Atlantic Investment Office President and Scotiabank U.S. CEO Kevin Felix as Strategic Advisor	AQ
Sep. 01	Netramark Holdings Inc. Announces Appointment of Keith M. Fournier to Board of Directors	CI
Sep. 01	NetraMark Strengthens Board of Directors with Appointment of Veteran Pharmaceutical Executive Dr. Keith Fournier	AQ
Aug. 27	NetraMark to Participate in the H.C. Wainwright 28th Annual Global Investment Conference	AQ
Aug. 20	NetraMark Corporate Update Highlights Record C$3.4 Million in Fiscal 2026 Contract Bookings, Up 645% from Previous Annual High	AQ
Aug. 14	NetraMark Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2026	CI
Jul. 13	NetraMark Engages AM Public Relations to Support Strategic Communications and Market Awareness	AQ
Jul. 09	NetraMark Up 11% as It Signs a New Contract To Analyze Phase 2 Neurodegeneration Trial Data	MT
Jul. 09	NetraMark Holdings Inc. Signs Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner	CI
Jul. 09	NetraMark Signs New Contract To Analyze Phase 2 Neurodegeneration Trial Data With Contract Research Organization Partner	AQ
Jun. 29	NetraMark to Perform AI-Assisted Analysis of Clinical Trial Data For Biopharm Company	MT
Jun. 29	NetraMark Holdings Inc. Signs NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company	CI
Jun. 29	NetraMark Signs New NetraAI Clinical Trial Analysis Agreement with Late-Stage Biopharmaceutical Company	AQ
Jun. 09	NetraMark Announces Presentation at Sidoti Small Cap Conference on June 18, 2026	AQ
May. 25	Upcoming Meeting Dates - May 25, 2026	NE
May. 20	NetraMark to Present at the American Society of Clinical Psychopharmacology Annual Meeting	AQ
May. 14	NetraMark Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026	CI
May. 14	NetraMark Provides Second Quarter Update and Highlights Continued Commercial, Scientific, Regulatory and Capital Markets Momentum	AQ
May. 07	NetraMark Announces Change To Board Of Directors	AQ
May. 07	NetraMark Holdings Inc. Announces Resignation of Lawrence Guy as Director, Effective May 7, 2026	CI
May. 05	NetraMark Holdings Inc. (AIAI) Opens the Market	NE
May. 04	NetraMark Appoints Dr. Panteli Theocharous As Fractional Chief Medical Officer, Strengthening Clinical Leadership To Accelerate Global Adoption of NetraAI	AQ
May. 04	NetraMark Holdings Inc. Announces Executive Changes	CI